SMT201700002B - Particelle virali rilasciate dopo l’infezione di cellule di mammifero mediante citomegalovirus umano (hcmv) contenenti una proteina di fusione e loro utilizzo - Google Patents
Particelle virali rilasciate dopo l’infezione di cellule di mammifero mediante citomegalovirus umano (hcmv) contenenti una proteina di fusione e loro utilizzoInfo
- Publication number
- SMT201700002B SMT201700002B SM201700002T SM201700002T SMT201700002B SM T201700002 B SMT201700002 B SM T201700002B SM 201700002 T SM201700002 T SM 201700002T SM 201700002 T SM201700002 T SM 201700002T SM T201700002 B SMT201700002 B SM T201700002B
- Authority
- SM
- San Marino
- Prior art keywords
- mammalus
- hcmv
- fusion protein
- viral particles
- particles released
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/245—Herpetoviridae, e.g. herpes simplex virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
- A61P31/22—Antivirals for DNA viruses for herpes viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/40—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/16011—Herpesviridae
- C12N2710/16111—Cytomegalovirus, e.g. human herpesvirus 5
- C12N2710/16141—Use of virus, viral particle or viral elements as a vector
- C12N2710/16143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/16011—Herpesviridae
- C12N2710/16111—Cytomegalovirus, e.g. human herpesvirus 5
- C12N2710/16161—Methods of inactivation or attenuation
- C12N2710/16162—Methods of inactivation or attenuation by genetic engineering
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Virology (AREA)
- Genetics & Genomics (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Biotechnology (AREA)
- Medicinal Chemistry (AREA)
- General Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Microbiology (AREA)
- Immunology (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Plant Pathology (AREA)
- Physics & Mathematics (AREA)
- Biophysics (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Pulmonology (AREA)
- Transplantation (AREA)
- AIDS & HIV (AREA)
- Tropical Medicine & Parasitology (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP10003712 | 2010-04-06 | ||
| EP11713689.5A EP2556150B1 (en) | 2010-04-06 | 2011-04-06 | Viral particle released after infection of mammalian cells by human cytomegalovirus (hcmv) containing a fusion protein and use thereof |
| PCT/EP2011/001712 WO2011124371A1 (en) | 2010-04-06 | 2011-04-06 | Viral particle released after infection of mammalian cells by human cytomegalovirus (hcmv) containing a fusion protein and use thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SMT201700002B true SMT201700002B (it) | 2017-03-08 |
Family
ID=43923731
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SM201700002T SMT201700002B (it) | 2010-04-06 | 2017-01-02 | Particelle virali rilasciate dopo l’infezione di cellule di mammifero mediante citomegalovirus umano (hcmv) contenenti una proteina di fusione e loro utilizzo |
Country Status (25)
| Country | Link |
|---|---|
| US (1) | US9486517B2 (it) |
| EP (1) | EP2556150B1 (it) |
| JP (1) | JP5827312B2 (it) |
| KR (2) | KR20170108167A (it) |
| CN (1) | CN102933706B (it) |
| AU (1) | AU2011238085B2 (it) |
| BR (1) | BR112012025392B1 (it) |
| CA (1) | CA2795346C (it) |
| CY (1) | CY1118138T1 (it) |
| DK (1) | DK2556150T3 (it) |
| ES (1) | ES2601850T3 (it) |
| HR (1) | HRP20161556T1 (it) |
| HU (1) | HUE030704T2 (it) |
| IL (1) | IL222229A (it) |
| LT (1) | LT2556150T (it) |
| MX (1) | MX2012011639A (it) |
| MY (1) | MY162335A (it) |
| PL (1) | PL2556150T3 (it) |
| PT (1) | PT2556150T (it) |
| RS (1) | RS55421B1 (it) |
| RU (1) | RU2623172C2 (it) |
| SG (2) | SG10201502271RA (it) |
| SI (1) | SI2556150T1 (it) |
| SM (1) | SMT201700002B (it) |
| WO (1) | WO2011124371A1 (it) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE102011101446A1 (de) * | 2011-05-10 | 2012-11-15 | Aicuris Gmbh & Co. Kg | Herstellung von "Dense Bodies" (DB) |
| WO2015048744A2 (en) | 2013-09-30 | 2015-04-02 | Moderna Therapeutics, Inc. | Polynucleotides encoding immune modulating polypeptides |
| WO2017070613A1 (en) | 2015-10-22 | 2017-04-27 | Modernatx, Inc. | Human cytomegalovirus vaccine |
| US10611800B2 (en) | 2016-03-11 | 2020-04-07 | Pfizer Inc. | Human cytomegalovirus gB polypeptide |
| AU2017345766A1 (en) | 2016-10-21 | 2019-05-16 | Modernatx, Inc. | Human cytomegalovirus vaccine |
| JP7449246B2 (ja) | 2018-06-08 | 2024-03-13 | ワクチン プロジェクト マネジメント ゲーエムベーハー | ウイルス粒子ベースのワクチン |
| EP3587566A1 (en) | 2018-06-29 | 2020-01-01 | Bodo Plachter | Hcmv vaccine strain |
| US11629172B2 (en) | 2018-12-21 | 2023-04-18 | Pfizer Inc. | Human cytomegalovirus gB polypeptide |
| TWI810589B (zh) | 2020-06-21 | 2023-08-01 | 美商輝瑞股份有限公司 | 人巨細胞病毒糖蛋白Ｂ（ｇＢ）多肽 |
| US11406703B2 (en) | 2020-08-25 | 2022-08-09 | Modernatx, Inc. | Human cytomegalovirus vaccine |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5733540A (en) * | 1995-03-08 | 1998-03-31 | Lee; Peter Poon-Hang | Protection from viral infection via colonization of mucosal membranes with genetically modified bacteria |
| DE19910044A1 (de) | 1999-03-08 | 2000-09-14 | Bodo Plachter | Virale Partikel, die nach Infektion durch humanes Cytomegalovirus freigesetzt werden und ihre Verwendung als Impfstoff |
| WO2006004661A1 (en) | 2004-06-25 | 2006-01-12 | Medimmune Vaccines, Inc. | Recombinant human cytomegalovirus and vaccines comprising heterologous antigens |
-
2011
- 2011-04-06 LT LTEP11713689.5T patent/LT2556150T/lt unknown
- 2011-04-06 RU RU2012146775A patent/RU2623172C2/ru active
- 2011-04-06 JP JP2013503035A patent/JP5827312B2/ja active Active
- 2011-04-06 CN CN201180027797.9A patent/CN102933706B/zh active Active
- 2011-04-06 MY MYPI2012004446A patent/MY162335A/en unknown
- 2011-04-06 SG SG10201502271RA patent/SG10201502271RA/en unknown
- 2011-04-06 AU AU2011238085A patent/AU2011238085B2/en active Active
- 2011-04-06 PT PT117136895T patent/PT2556150T/pt unknown
- 2011-04-06 PL PL11713689T patent/PL2556150T3/pl unknown
- 2011-04-06 CA CA2795346A patent/CA2795346C/en active Active
- 2011-04-06 EP EP11713689.5A patent/EP2556150B1/en active Active
- 2011-04-06 SG SG2012071189A patent/SG184261A1/en unknown
- 2011-04-06 WO PCT/EP2011/001712 patent/WO2011124371A1/en active Application Filing
- 2011-04-06 MX MX2012011639A patent/MX2012011639A/es active IP Right Grant
- 2011-04-06 ES ES11713689.5T patent/ES2601850T3/es active Active
- 2011-04-06 BR BR112012025392-1A patent/BR112012025392B1/pt active IP Right Grant
- 2011-04-06 HU HUE11713689A patent/HUE030704T2/en unknown
- 2011-04-06 KR KR1020177025664A patent/KR20170108167A/ko not_active Application Discontinuation
- 2011-04-06 RS RS20161007A patent/RS55421B1/sr unknown
- 2011-04-06 US US13/639,636 patent/US9486517B2/en active Active
- 2011-04-06 DK DK11713689.5T patent/DK2556150T3/en active
- 2011-04-06 KR KR1020127028033A patent/KR101839535B1/ko active IP Right Grant
- 2011-04-06 SI SI201131016A patent/SI2556150T1/sl unknown
-
2012
- 2012-09-27 IL IL222229A patent/IL222229A/en active IP Right Grant
-
2016
- 2016-10-25 CY CY20161101076T patent/CY1118138T1/el unknown
- 2016-11-22 HR HRP20161556TT patent/HRP20161556T1/hr unknown
-
2017
- 2017-01-02 SM SM201700002T patent/SMT201700002B/it unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SMT201700002B (it) | Particelle virali rilasciate dopo l’infezione di cellule di mammifero mediante citomegalovirus umano (hcmv) contenenti una proteina di fusione e loro utilizzo | |
| HK1247628A1 (zh) | 多特異性fab融合蛋白及其使用方法 | |
| SMT201600285B (it) | Procedimento per la fabbricazione di una preparazione farmaceutica contenente ipp | |
| DK2780022T3 (da) | Farmaceutiske præparater af humane rpe-celler og anvendelser deraf | |
| CO7020851A2 (es) | Proteínas y péptidos modificados | |
| DK3459564T3 (da) | Plasmakallikreinbindende proteiner | |
| BR112013001603A2 (pt) | ''artigo absorvente descatável'' | |
| IL221748B (en) | Concentrated protein preparations and their uses | |
| JP2012010905A5 (ja) | パンツタイプ使い捨ておむつ | |
| BR112012032260A2 (pt) | ésteres de ácido 2-oxo-1,3-dioxolano-4-carboxílico,sua preparação e uso | |
| SG10201811256QA (en) | Serpin fusion polypeptides and methods of use thereof | |
| BR112013024493A2 (pt) | cristais de anticorpo antiesclerostina e formulações dos mesmos | |
| EP2477650B8 (en) | Virus like particles comprising target proteins fused to plant viral coat proteins | |
| DK2593060T3 (da) | Engangsble | |
| EP2887819A4 (en) | TRANSGENIC MICROALGUES AND THEIR USE FOR ORAL ADMINISTRATION OF PROTEINS | |
| BR112013022285A2 (pt) | proteína de fusão de fgfr-fc e o seu uso | |
| BR112012028633A2 (pt) | composição reticulada e artigo | |
| DK3095441T3 (da) | Hurtigt opløsende doseringsform af en oral vaccine under anvendelse af stivelse | |
| EP2800177A4 (en) | ACTIVE NEGATIVE ELECTRODE MATERIAL AND USE THEREOF | |
| ITMI20110836A1 (it) | Procedimento per la fabbricazione di una batteria a strato sottile ecorrispondente batteria a strato sottile | |
| DK2709656T3 (da) | Proteinmatrix-vaccinesammensætninger omfattende polykationer | |
| HK1223130A1 (zh) | 用於表徵人膜蛋白的功能和相互作用的病毒體展示陣列 | |
| EP3013960A4 (en) | Modified matrix proteins of vesicular stomatitis virus | |
| EP2755982A4 (en) | SILICULAR HETEROCYCLIC DERIVATIVES AND METHOD FOR THEIR USE FOR THE TREATMENT OF VIRUS DISEASES | |
| BR112013012040A2 (pt) | tratamento de câncer com dosagens elevadas de proteínas de fusão fdfr1 solúveis |